June 2026 Research Update

This month, two interview-based studies added a clearer picture of families' priorities and experiences. A study of caregivers of young children described the main symptom burdens of the disease [1] , while a multi-country transition study found that care feels high-burden when it is fragmented and smoother with continuity, a key contact person, and clear communication [2] .

For caregivers of 2 to 5 year old boys with neuronopathic MPS II, cognitive decline and disruption to family life were reported by every caregiver interviewed. Many also described frequent challenges with speech and communication, walking or climbing stairs, and hand movement, and these areas were often described as the most bothersome parts of daily life. [1]

In adults with MPS II and their caregivers, experiences moving from pediatric to adult services differed widely across and within countries. Interviews repeatedly pointed to practical features that make transition easier to manage, including continuity of care, having a key contact person, and helping patients build independence earlier, along with added educational and psychosocial supports. [2]

These findings mainly add understanding rather than changing treatment. They put patient and caregiver priorities into clear words that researchers and health systems can use when designing services or deciding what outcomes to measure in studies. What remains uncertain is how often these experiences apply outside the small interview groups, and whether the suggested transition supports consistently improve real-world outcomes when put into place. [1] [2]

This month brought progress on the behind-the-scenes work needed to make newborn screening results more consistent across laboratories. The study reported that standardized dried blood spot materials for proficiency testing performed with high accuracy across many labs, while also showing that occasional mix-ups can happen and need to be monitored. [3]

The program expanded its proficiency testing panel to include MPS II along with six other lysosomal diseases, and deployed materials to a large set of domestic and international laboratories. Reported performance was high in pilots and deployment, with 98% acceptable or correct results across 71 laboratories, but there were occasional misassignments (including between MPS I and MPS II) and some handling or data-reporting errors. [3]

This is lab-focused research, but it may matter over time because newborn screening depends on many labs producing reliable results. The study supports that labs can achieve very high agreement when using shared proficiency testing materials, while also clarifying that rare misclassifications can occur and are part of what these quality checks are designed to catch. It does not report on patient outcomes or how screening affects children with MPS II, so its impact is mainly on strengthening testing systems rather than changing care right now. [3]

This month included early-stage studies that explore possible future directions, but with results that are either negative in the lab or limited to one patient. Together, they help clarify what is not yet working reliably and what might be feasible in very specific situations, without establishing what will help most people with Hunter syndrome. [4] [5]

In laboratory testing using two patient-derived cell lines, a newly synthesized candidate pharmacological chaperone (a small molecule intended to help the IDS enzyme fold or function) did not reduce intracellular heparan sulfate storage at the doses tested. The known chaperone D2S0 also did not reduce heparan sulfate in these same cell experiments. [4]

In a single child with MPS II who had graft failure after an initial cord blood transplant, a second cord blood transplant using the same conditioning approach achieved durable engraftment with high donor chimerism. The reported course included serious complications after transplant, including infections and an inflammatory syndrome with hemophagocytosis, showing the complexity of this approach even when engraftment succeeds. [5]

These reports are mainly research signals rather than information that changes care. The cell-line study helps narrow the field by showing that one chaperone strategy did not lower stored material in the specific mutations tested, which can guide what gets improved or tested next. The transplant case report may be most relevant to families already discussing transplant in specialized settings, but it remains uncertain how often the same outcome would occur because it describes only one child and includes significant complications. [4] [5]